Table 1.
Patient Characteristics and Treatments
| Characteristic | n (%) |
|---|---|
| Total | 18 |
| Male/Female | 6 (33) / 12 (67) |
| Race/ethnicity | |
| Non-Hispanic white | 7 (39) |
| Hispanic | 4 (22) |
| Asian | 7 (39) |
| Mean age at diagnosis | 60y (range 32-81) |
| Positive smoking history | 4 (22) |
| Histological subtype | |
| Adenocarcinoma | 18 (100) |
| Ex20ins mutation subtype | |
| V769_D770insASV | 5 (28) |
| A767_V769dup | 5 (28) |
| S768_D770dup | 2 (11) |
| p.N771delinsGF | 1 (6) |
| M766_A767ins | 1 (6) |
| Unknown | 4 (22) |
| Co-mutations and other tumor markers | |
| TP53 | 7 (39) |
| PIK3CA | 1 (6) |
| APC | 1 (6) |
| ERBB2 | 1 (6) |
| PD-L1 (high expression, > 50%) | 1 (6) |
| CDK4 amplification | 1 (6) |
| Stage at systemic treatment initiation | |
| IV | 18 (100) |
| Location of metastases | |
| Brain | 3 (17) |
| Bone | 11 (61) |
| Liver | 5 (28) |
| Adrenals | 2 (11) |
| Prior local therapy | |
| Surgery | 1 (6) |
| Radiation | 14 (78) |
| Platinum-based chemotherapy regimen | |
| Carboplatin + pemetrexed | 10 (56) |
| Carboplatin + pemetrexed + bevacizumab | 5 (28) |
| Carboplatin + pemetrexed + pembrolizumab | 2 (11) |
| Carboplatin + paclitaxel + bevacizumab | 1 (6) |
| Line of therapy | |
| First-line | 17 (94) |
| Second-line | 1 (6) |